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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.039Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by pulmonary
vasculopathy with elevation of pulmonary artery pressure, often culminating in right ventricular failure.
GATA-6, a member of the GATA family of zinc-ﬁnger transcription factors, is highly expressed in quiescent
vasculature and is frequently lost during vascular injury. We hypothesized that endothelial GATA-6 may
play a critical role in the molecular mechanisms underlying endothelial cell (EC) dysfunction in PAH. Here
we report that GATA-6 is markedly reduced in pulmonary ECs lining both occluded and nonoccluded
vessels in patients with idiopathic and systemic sclerosis-associated PAH. GATA-6 transcripts are also
rapidly decreased in rodent PAH models. Endothelial GATA-6 is a direct transcriptional regulator of genes
controlling vascular tone [endothelin-1, endothelin-1 receptor type A, and endothelial nitric oxide
synthase (eNOS)], pro-inﬂammatory genes, CX3CL1 (fractalkine), 5-lipoxygenease-activating protein,
and markers of vascular remodeling, including PAI-1 and RhoB. Mice with the genetic deletion of GATA-6
in ECs (Gata6-KO) spontaneously develop elevated pulmonary artery pressure and increased vessel
muscularization, and these features are further exacerbated in response to hypoxia. Furthermore, innate
immune cells including macrophages (CD11bþ/F4/80þ), granulocytes (Ly6Gþ/CD45þ), and dendritic
cells (CD11bþ/CD11cþ) are signiﬁcantly increased in normoxic Gata6-KO mice. Together, our ﬁndings
suggest a critical role of endothelial GATA-6 deﬁciency in development and disease progression in PAH.
(Am J Pathol 2013, 182: 2391e2406; http://dx.doi.org/10.1016/j.ajpath.2013.02.039)Supported by NIH grants RO1 AR42334 (M.T.) and T32 AR 050958
(A.G.), and the Entelligence Young Investigators Award from Actelion
Pharmaceuticals US, Inc. (A.G.).
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tology, University of Tokyo, Tokyo, Japan.Pulmonary arterial hypertension (PAH) is a severe vascular
disorder characterized by an increase in resistance and blood
pressure in the pulmonary artery (PA) or lung vasculature.1
The key pathological features of PAH occur in small PAs
and include vasoconstriction, thrombosis, and inﬂammation,
leading to intimal proliferation and ﬁbrosis. Elevations in
pulmonary vascular resistance and PA stiffness lead to pres-
sure and volume overloading of the right ventricle, and
eventually cause right heart failure and death. PAH is one of
ﬁve groups within the pulmonary hypertensionWorld Health
Organization clinical classiﬁcation system, which contains
various forms including patients with idiopathic pulmonary
arterial hypertension (IPAH) and familial pulmonary arterial
hypertension (FPAH), and is associated with connective
tissue diseases, primarily systemic sclerosis (SSc) pulmonary
arterial hypertension (SSc-PAH).1 SSc-PAH has similarstigative Pathology.
.clinical and histopathological features such as IPAH;
however, it is unclear whether the molecular mechanisms
responsible for the pathogenesis of the two forms are similar.2
The cellular and molecular processes underpinning
pathological vascular remodeling in PAH are complex and
involve phenotypic alterations in different cell types within
the vascular wall with further contributions from the circu-
lating immune and progenitor cells.3 Although the inciting
events remain poorly deﬁned, current theories suggest that
PAH is initiated by the disruption of EC homeostasis
Ghatnekar et alleading to an imbalance of vasoactive factors and production
of prothrombotic and pro-inﬂammatory mediators. Genetic
studies have linked dysregulated bone morphogenetic protein
signaling to the pathogenesis of FPAH and IPAH. Hetero-
zygous mutations of the bone morphogenetic protein receptor
type II (BMPR2) were found in 50% to 70% of FPAH cases
and 11% to 40% sporadic of IPAH cases.4 Furthermore,
a subset of patients with hereditary hemorrhagic telangiec-
tasia carrying mutations in activin receptor-like kinase or
endoglin genes also develops PAH.5 Consistently, mice with
the genetic ablation of Bmpr2 gene are predisposed to
develop PAH.6 In contrast to FPAH and IPAH, BMPR2 and
activin receptor-like kinase 1 mutations, so far, were not
found in patients with SSc-PAH, suggesting that other
molecular mechanisms may underlie the disease process in
SSc-PAH.7,8 Notably, patients with SSc-PAH have higher
disease mortality and are less responsive to currently used
therapies compared to patients with IPAH.9 In addition to
autoimmunity, structural changes in systemic microcircula-
tion and inﬂammation, present from an early stage of the
disease, appear to be more severe in patients with SSc-PAH,
and are likely to contribute to SSc-PAH.9 Recent compre-
hensive gene analyses that compared lung tissues from
patients with IPAH and SSc-PAH have further supported the
role of inﬂammation in both forms of PAH.10 The latter study
has also revealed common and unique gene expression
patterns in each disease. Despite recent advances in the
elucidation of the cellular processes contributing to the
development of PAH, the role of ECs in the initiation and
progression of PAH remains poorly understood.
GATA-6 is one of six mammalian GATA factors that are
highly conserved transcription factors with two tandem zinc
ﬁngers that interact with other transcriptional regulators and
bind the canonical DNA motif, (G/A)GATA(A/T).11 Human
GATA-6 is expressed in a wide array of tissues (heart, lung,
liver, kidney, pancreas, spleen, ovary, and small intestine),
where it is believed tomaintain the differentiated phenotype of
the cells within these tissues.12 GATA-6 is expressed in
quiescent vascular smooth muscle cells (VSMCs) and may
contribute to the maintenance of the contractile phenotype of
VSMCs.13,14 Furthermore, GATA-6 is rapidly decreased in
proliferating VSMCs in vitro12 and in injured vasculature.15
Rescuing GATA-6 levels in a balloon-mediated injury of
carotid arteries results in a higher degree of VSMC differenti-
ation and signiﬁcant reduction of neointimal formation in the
rat.15 Furthermore, GATA-6 functions as a transcriptional
repressor of Tenascin C,16 an extracellular matrix protein
associated with progression of PAH.17 These studies suggest
that loss of GATA-6 may be a key component in the patho-
genesis of injury-induced vascular lesions. GATA-6 is also
signiﬁcantly reduced in intramyocardial arteries of spontane-
ously hypertensive rats.18 Importantly, GATA-6 transcript
levels were found to be down-regulated concurrent with
development and progression of pulmonary hypertension in
rats.19 Administration of simvastatin ameliorated increased
pulmonary hypertension and vascular remodeling in this2392model, which correlated with normalization of GATA-6
expression levels.19 Taken together, these observations indi-
cate that GATA-6 may play a role in the phenotypic changes
occurring during vascular remodeling in PAH.
Although GATA-6 vascular function has been investi-
gated, mostly inVSMCs, a recent study has demonstrated that
GATA-6 plays a vital role in angiogenesis and EC survival.20
Importantly, compared transcriptomes of dermal microvas-
cular ECs from normal subjects and patients affected by SSc
revealed that GATA-6 may be down-regulated more than
twofold in lesional skin with vasculopathy.21 Given that
GATA-6 is down-regulated in various animal models of
vascular injury, the present study was undertaken to investi-
gate the potential contribution ofGATA-6 to the development
of PAH focusing on the role of GATA-6 in ECs. We
demonstrate that GATA-6 is down-regulated in pulmonary
vascular lesions of PAHpatients. Furthermore, the expression
of GATA-6 is rapidly reduced in the monocrotaline (MCT)
rat model and in the chronic hypoxia mouse model of PAH.
Consistent with these ﬁndings, mice with the conditional
knockdown of GATA-6 in ECs spontaneously develop
elevated pulmonary arterial pressure and demonstrate
increased vessel muscularization, as well as increased pul-
monary inﬂammation. Microarray analysis coupled with
chromatin immunoprecipitation assays reveal that GATA-6
regulates a set of genes linked to EC dysfunction previously
associated with PAH. CX3CL1 (fractalkine) was among the
genes that were signiﬁcantly upregulated in GATA-6 deﬁ-
cient ECs, suggesting that GATA-6 down-regulation might
also directly contribute to the increased inﬂammatory milieu.
Together, these studies provide novel insights into the role of
EC dysfunction during pathogenesis of PAH.
Materials and Methods
Immunohistochemical Analysis of Skin and Lung
Specimens
The study group for the lung analysis included ﬁve IPAH lung
specimens, nine SSc-PAH lung specimens, and four control
specimens. Lung samples were obtained from patients with
IPAH or SSc-PAH who underwent lung transplantation at the
University of Pittsburgh Medical Center, under a protocol
approved by institutional board review. Normal lung tissue
specimens were obtained from donors, whose lungs were not
used for tissue transplantation. Immunohistochemistry was
performed on 4 mm serial sections using a Vectastain ABC kit
(Vector Laboratories, Burlingame, CA) according to the
manufacturer’s instructions. Sections were subjected to a
5-minute antigen retrieval treatment in a stainless steel pres-
sure cooker (Fagor, Basque Country, Spain) with antigen
unmasking solution (Vector Laboratories, Burlingame, CA).
Antibodies used included GATA-6 (1:100; Santa Cruz
Biotechnology, Santa Cruz Biotechnology) or CD31 (1:1500;
Santa Cruz Biotechnology). Binding of primary antibody to the
tissue was visualized with 3.30-diaminobenzidine solutionajp.amjpathol.org - The American Journal of Pathology
Table 1 Primers Used for Human RT-qPCR
Gene Primers
PLA2G4C 50-CCACTCACAACTTCCTGTACAAAC-30 Forward
50-ATGGCTAAACCAGCATCCA-30 Reverse
FLAP 50-GTCTGCGGGGCTACTTTG-30 Forward
50-TGCCTCACAAACAAGTACATCA-30 Reverse
RhoB 50-TAAGGGTGGTGATGGGTGAG-30 Forward
50-GGGTTGGAAAGATGGTCAAG-30 Reverse
MMP-10 50-TGGACAGAAGATGCATCAGG-30 Forward
50-CTTCAGTGTTGGCTGAGTGAA-30 Reverse
MMP-1 50-TCTGGGGTGTGGTGTCTCA-30 Forward
50-GCCTCCCATCATTCTTCAGGTT-30 Reverse
PAI-1 50-CCCAGCTCATCAGCCACT-30 Forward
50-GAGGTCGACTTCAGTCTCCAG-30 Reverse
CX3CL1 50-CCACCTTCTGCCATCTGAC-30 Forward
50-ATGTTGCATTTCGTCACACC-30 Reverse
eNOS 50-AGGAACCTGTGTGACCCTCA-30 Forward
50-TATCCAGGTCCATGCAGACA-30 Reverse
ACE 50-AACATGAGCAGGATCTACTCCAC-30 Forward
50-AGCCAGGATGTTGGTGAGA-30 Reverse
EDNRA 50-CTCAACCTCTGCGCTCTTAGTG-30 Forward
50-CCAAAGGAATCCCAATTCCC-30 Reverse
ET-1 50-GCTCGTCCCTGATGGATAAA-30 Forward
50-CCATACGGAACAACGTGCT-30 Reverse
GATA-6 50-TTGTGGACTCTACATGAAACTCCA-30 Forward
50-TTATGTTCTTAGGTTTTCGTTTCCTG-30 Reverse
GATA-6 Regulates Vessel Remodeling(Vector Laboratories, Burlingame,CA).Hematoxylinwas used
as a counterstain. Either normal rabbit or goat IgG was used as
a control. The number of positively stained ECs in arterioles,
venules, and capillaries were counted in more than 25 ﬁelds for
each specimen. More than 120 vessels and 340 ECs were
counted per specimen.
In Situ Hybridization
In situ hybridization was performed as described earlier.22
Brieﬂy, a 712-bp human GATA-6 probe was synthesized
fromaGATA-6 cDNAexpression plasmid using the following
primers: GATA-6 forward 50-ATGACTCCAACTTCCACC-
TCT-30; GATA-6 reverse 50-CAGCCTCCAGAGATGTGT-
AC-30. The PCR product was subject to digoxygenin-UTP
labeling using the DIG (Sp6/T7) RNA labeling kit (Roche
Diagnostics, Basel, Switzerland) and puriﬁcation by RNeasy
clean up kit (Qiagen, Hilden, Germany). Sections were incu-
bated overnight with the GATA-6 sense or antisense probe
(ﬁnal concentration 200 ng/mL). Immuno-BCIP/NBT liquid
substrate (MPBiomedicals, Santa Ana, CA) was used to detect
hybridization.Apolyd(T) probewas used as a control for intact
RNA.
Cell Culture
Human PA ECs (HPAECs) were purchased from Lonza
(Walkersville, MD) and cultured in complete endothelial
growth medium-2. The cells were used at passage number
5e8 for all experiments.
Transfection of siRNA Oligos
Conﬂuent cultures of HPAECs were transfected with
50 nmol/L of siRNA directed against GATA-6 (Dharmacon,
Waltham, MA) and nonsilencing siRNA (Qiagen) using
Genesilencer (Genlantis, San Diego, CA). Cells were incu-
bated for 72 hours and either total RNA was prepared using
TRI reagent (MRC, Inc., Cincinnati, OH) according to the
manufacturer’s protocol or whole cell extracts were prepared.
Quantitative RT-PCR
Quantitative RT-PCR was performed as previously
described.23 Sequences for all primers used in these studies
are shown in Tables 1 and 2.
Immunoblotting for Cell Extracts
Nitrocellulose membranes were blocked with nonfat dry milk
in T-TBS and then probed overnight with antieGATA-6 (sc-
9055; 1:500; Santa Cruz Biotechnology), anti-RhoB (sc-180;
1:250; Santa Cruz Biotechnology), antieendothelial Nitric
Oxide Synthase (eNOS; sc-654; 1:500; Santa Cruz Biotech-
nology), antieMMP-1 (MAB3307; 1:1000; Millipore, Bill-
erica MA), anti-MMP10 (MS-8220-PO; 1:500; NeoMarkers,
Fremont, CA), or PAI-1 (395R; 1:250; American Diagnostics,The American Journal of Pathology - ajp.amjpathol.orgStamford, CT). Blots were incubated for at least 1 hour in the
appropriate horseradish peroxidase coupled-secondary anti-
bodies (1:3000) and developed using the Chemiluminescent
detection kit (Pierce, Waltham, MA). Band intensities were
determined by densitometric analysis.
ELISA
Cell culture supernatants were subjected to enzyme-linked
immunosorbent assay (ELISA) using a human Quantikine
CX3CL1 ELISA kit (R&D Systems, Minneapolis, MN)
following the manufacturer’s instructions.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as previ-
ously described.24 Relative fold enrichment of DNA was
determined by PCR using speciﬁc primers for the indicated
gene promoters (Table 3), followed by agarose gel electro-
phoresis. Primers that ﬂank a region of genomic DNA
between the glyceraldehydes-3-phosphate dehydrogenase
gene and the CNAP1 gene were used a negative control.
Mice
Gata6ﬂox/ﬂox mice were purchased from Jackson Labora-
tory (Bar Harbor, ME). The mouse line, which contains LoxP
elements in introns ﬂanking exon 2 of the Gata-6 gene, was
bred with mice expressing Cre recombinase under the control
of the endothelial-speciﬁc VE-cadherin promoter (Jackson2393
Table 3 Primers Used for ChIP
Promoter Primers
Negative
control
50-ATGGTTGCCACTGGGGATC-30 Forward
50-TGCCAAAGCCTAGGGGAAGA-30 Reverse
PLA2G4C 50-ATGGCTCCACCAGGTAGGTA-30 Forward
50-AGCTCATGAGGCTCTCCACA-30 Reverse
FLAP 50-CAGTGGTCCATGTTCCCTTT-30 Forward
50-AGGTGGCTGCCTGGTATTCT-30 Reverse
RhoB 50-ACAGGCATGAGGTACTGTGC-30 Forward
50-CGGTCTCTGTCAGTTGTTG-30 Reverse
MMP-10 50-TACCAAGCTTGTCAGCTCTG-30 Forward
50-GGTGATACAGCCTACATCAG-30 Reverse
MMP-1 50-AATGCTGCCTAGCACCAAGG-30 Forward
50-AGAGCCTTACCTGAGAAGAC-30 Reverse
PAI-1 50-AGGCAGGAGAACCACTTGAA-30 Forward
50-ACTGGCTAGCAGTGGGTGAG-30 Reverse
CX3CL1 50-CTTCGGTGAGAGCCTGTTG-30 Forward
50-CCCTGTTAGCCCAAAGAACA-30 Reverse
eNOS 50-TGGTGCCACATCACAGAAGG-30 Forward
50-TCTAAAGCCTCAGCTCCACG-30 Reverse
EDNRA 50-CGCTGGAACCTTCCATAGTC-30 Forward
50-AAGCTTAGAGGCCGTTGAGG-30 Reverse
ET-1 50-ATCTCCCCCTGGTGTTCTTC-30 Forward
50-TTAGGCACATGCCCAGTCTT-30 Reverse
VE-Cadherin 50-GGTTCTTCTGGGCTCTGATC-30 Forward
50-GGATATTGGGTGGAGTCAAG-30 Reverse
ChIP, chromatin immunoprecipitation.
Table 2 Primers Used for Mouse RT-qPCR
Gene Primers
PLA2G4C 50-GAGGACCTTCTGGCTGATTG-30 Forward
50-CCAGCATGATGAGGAGTGAA-30 Reverse
Flap 50-CTGCTTCTCATCCCCTGATT-30 Forward
50-TTGCGTTATGATGCGTCTCT-30 Reverse
RhoB 50-CAGACTGCCTGACATCTGCT-30 Forward
50-GTGCCCACGCTAATTCTCAG-30 Reverse
MMP-10 50-AGGAAGTGACCCCACTCAC-30 Forward
50-GGGTAAAAGTCTCCGTGTTCTC-30 Reverse
Pai-1 50-AGGATCGAGGTAAACGAGAGC-30 Forward
50-GCGGGCTGAGATGACAAA-30 Reverse
CX3CL1 50-CGCGTTCTTCCATTTGTGTA-30 Forward
50-CATGATTTCGCATTTCGTCA-30 Reverse
eNOS 50-CCAGTGCCCTGCTTCATC-30 Forward
50-GCAGGGCAAGTTAGGATCAG-30 Reverse
Ace 50-TTGATGGAAGCATCACCAAG-30 Forward
50-GGGCACAGACCCTGATACTT-30 Reverse
EDNRA 50-TGATCGTTTCATCTTCTTTCAATG-30 Forward
50-CCTCATCAGACGGTCTTCCT-30 Reverse
Et-1 50-CTGCTGTTCGTGACTTTCCA-30 Forward
50-TCTGCACTCCATTCTCAGCTC-30 Reverse
Gata-6
(mouse)
50-GGTGCTCCACAGCTTACAGG-30 Forward
50-GCCGTCTCGTCTCCACAG-30 Reverse
Gata-6 (rat) 50-ACGCATGCGGTCTCTACAGT-30 Forward
50-AGTCCAAGCCGTCGTGAT-30 Reverse
Hif1a 50-GCACTAGACAAAGTTCACCTGAGA-30 Forward
50-CGCTATCCACATCAAAGCAA-30 Reverse
Hif1b 50-TGCCTCATCTGGTACTGCTG-30 Forward
50-TGTCCTGTGGTCTGTCCAGT-30 Reverse
Hif1a 50-GGTTAAGGAACCCAGGTGCT-30 Forward
50-GGGATTTCTCCTTCCTCAGC-30 Reverse
Ghatnekar et alLaboratory). For hypoxic conditions, mice were placed in
a hypoxic chamber (10% oxygen) (BioSpherix, Lacona, NY).
Mouse EC Isolation
Two different methods were used to isolate mouse ECs. In the
ﬁrst method, lung and hearts were excised aseptically and
transferred to ice-cold Dulbecco’s modiﬁed Eagle’s medium.
Under the hood, the tissues were minced ﬁnely, followed by
digestion in 15 mL of 1 mg/mL warm collagenase (Roche
Diagnostics) at 37C for 45 minutes with gentle agitation. The
digested tissue was aspirated and transferred to a 20 mL
syringe with a 14 g cannula attached and the clumps were
triturated. The single cell suspension was then passed through
a 70 mm cell strainer and subjected to centrifugation. The cell
pellet was resuspended in 0.1% bovine serum albumin/PBS
and anti-platelet EC adhesion molecule-1 antibody conjugated
Dynabeads (Invitrogen, Carlsbad, CA) were added for 12
minutes with rotation. Beads were prepared according to the
manufacturer’s instructions. After washing, cells were plated
on gelatin-coated 60 mm dishes. When cells were 70% to
80% conﬂuent, they were sorted a second time with antie
ICAM-2 antibody-conjugated Dynabeads. Cultured ECs were
characterized by a cobblestone morphology, uptake of ﬂuo-
rescent acetylated LDL (Biomedical Technologies Inc,2394Stoughton, MA), and speciﬁc staining for CD31. Cells were
harvested at passages 2 to 3 for analyses.
In the second method, which was used for isolation of fresh
cells for mRNA analyses, mouse lung tissue was ﬁnely minced
and digested with 0.1 collagenase A (Roche Diagnostics),
2.4 units/mL dispase (Roche Diagnostics), and 6 units/mL
DNase I (Qiagen) at 37C for 1 hour. Debris was removed by
sequential ﬁltration through 70 and 40 mm ﬁlters (BD Biosci-
ences, San Jose, CA). Cells were stained with ﬂuorochrome-
conjugatedmouse-speciﬁc antibodies CD31-FITC/CD45-APC
from BD Biosciences and then CD31þ/CD45 cells were sor-
ted by MoFlo High Speed Cell Sorter (BD Biosciences).
Hemodynamic Analysis
Systolic blood pressure, diastolic blood pressure, mean
pressure, heart pulse rate, and blood volume were measured
noninvasively by determining the tail blood volume with
a volume pressure recording sensor and an occlusion tail-
cuff (CODA System; Kent Scientiﬁc, Torrington, CT).
Echocardiography
Transthoracic echocardiography was performed using a
Vevo 770 High-Resolution Imaging System with 30-MHz
RMV-707b scanning head (VisualSonics, Toronto, Canada).
Pulmonary acceleration time (PAT) and PAT as a fraction of
ejection time were measured from the pulse-wave Doppler
recordings of the PA blood ﬂow as previously described at
baseline and after 1 month and 2 months of hypoxia.25ajp.amjpathol.org - The American Journal of Pathology
GATA-6 Regulates Vessel RemodelingMeasurement of RV Pressure
After the open chest method,26 right ventricular (RV) pres-
sures were measured using a high-ﬁdelity pressure sensor
catheter inserted directly into the right ventricle. Brieﬂy, mice
were anesthetized using isoﬂurane and mechanically venti-
lated through a 22-gauge cannula [130 breaths per minute,
Harvard Apparatus (Holliston, MA) rodent ventilator]. Body
temperatures were maintained on a heating pad. The thoracic
cage was pulled upward by the xiphoid cartilage and the dia-
phragm was carefully removed to expose the heart. Cauter-
ization of the tissuewas used tominimize blood loss. The heart
was superfused with a few drops of warm saline. The tip of
a 25-guage needle was immersed in heparin solution (10,000
USP units/mL) and gently inserted into the right ventricle
using the right coronary artery as a guide. The needle was
retracted and the tip of a pressure catheter transducer (Micko-
Tip, SPR-839; Millar Instruments, Houston, TX) was inserted
through the small aperture. Pressurewaveformswere recorded
for at least 2 minutes for each mouse in real-time using the
PowerLab Chart 5 version 5.3 data acquisition system and
analysis software (ADInstruments, Colorado Springs, CO).
RV pressures were calculated by averaging at least 20 cardiac
cycles for each mouse.
Mouse Histology and Pulmonary Vascular Morphometry
Mice were euthanized by CO2 gas and the right lung (with
the heart) was inﬂated and ﬁxed overnight in 4% para-
formaldehyde. After ﬁxation, the lung was dehydrated
through a series of alcohol gradients and embedded in
parafﬁn. Five mm sections were cut, deparafﬁnized in Histo-
Clear (National Diagnostics, Atlanta, GA), and stained with
an antiea-smooth muscle actin antibody (dilution 1:800,
clone 1A4; Sigma, St. Louis, MO), an antiehuman von
Willebrand factor antibody (dilution 1:800; Dako, Hamburg,
Germany), and an antiemouse Mac3 antibody (dilution 1:50;
BD Pharminogen, San Jose, CA) using a Vectastain ABC kit
(Vector Laboratories). Peripheral PAs ranging in 20 to 70 mm
in size were counted in at least four ﬁelds at 20 magniﬁ-
cation with a Zeiss (Thornwood, NY) Axiovert-35 inverted
microscope. Counted vessels were categorized into non-
muscularized, partially muscularized (1% to 74% of medial
layer has positive a-smooth muscle actin [SMA] staining), or
fully muscularized (75% to 100% of medial layer has posi-
tive a-SMA staining). Percentages of vessels in each cate-
gory were calculated by dividing the total number of vessels
in each category by the total number of vessels counted in the
ﬁeld. Percent wall thickness (the thickness between the inner
and outer boundary of the a-SMA-staining medial layer) was
measured in fully muscularized PAs at two sites along the
blood vessel using ImageJ software version 1.45s (NIH,
Bethesda, MD). External diameters were measured concur-
rently for the same vessel and the percentage medial wall
thickness was calculated as (wall thickness1 þ wall thick-
ness2)  100 per external diameter.The American Journal of Pathology - ajp.amjpathol.orgAnalysis of Cardiac Valves in Wt and Gata6 Conditional
Knockout Mice
Hearts isolated from adult wild-type (Wt) and Gata6 condi-
tional knockout mice were ﬁxed in a 4% paraformaldehyde.
Heart tissues were sectioned at 10 mm and stained with H&E,
similar to previously described methods.27 Valve histology
was analyzed by comparison of serial sections of Wt (2) and
Gata6-KO (3) mice under normoxic and hypoxic conditions.
Ventricular Weight Measurements
The ventricles were excised and weighed. The weight ratio
of the right ventricle to the left ventricle plus septum was
calculated as indices of RV hypertrophy.
MCT-Induced Rat Model of PAH
Male Sprague-Dawley rats (200 to 225 g body weight) were
dosed with a single 60 mg/kg body mass subcutaneous
injection of MCT. Control rats received an equal volume of
saline. Rats were housed in a 12/12-light/dark cycle and
given standard rat chow and water ad libitum. They were
euthanized at 1, 3, 5, 10, and 20 days postinjection.
RNA Isolation from Mouse and Rat Lungs and Real
Time-PCR
RNA was isolated and puriﬁed using the Qiagen RNeasy kit
(Qiagen) following the manufacturer’s instructions. RT-
PCR was performed as previously described using the
primers listed in Table 2.
Immunoprecipitation and Immunoblotting for Rat
Lungs
Lungs were homogenized in radioimmunoprecipitation assay
buffer using a douncer. Then1000mg of extractwas pre-cleared
with protein G-Sepharose beads (Amersham Biosciences,
Pittsburgh, PA), and incubated with 1 mg of monoclonal mouse
anti-GATA6 antibody (R&D Systems) overnight at 4C with
gentle rotation. Protein G-Sepharose beads were added and the
precipitated proteins were subjected to SDS-PAGE. Immuno-
blotting for Gata-6 was performed as previously described for
cell extracts. As an input control, 10 mL of the pre-cleared
extract was subjected to SDS-PAGE and membranes were
incubatedwith amouse antieb-actin antibody (1:5000,Sigma).
Rat Lung Histology and Immunohistochemistry
Sections (5 mm thick) were stained with Masson’s tri-
chrome stain and H&E stain using standard techniques. Im-
munohistochemical analysis was performed using the standard
avidin-biotin-peroxidase method as previously described.
Sections were incubated in primary antibody against a-SMA
(Thermo Scientiﬁc, Neomarkers, Kalamazoo, MI).2395
Ghatnekar et alFlow Cytometry Analysis
Flow cytometry was performed on an LSRII cytometer (BD
Biosciences) and data were analyzed using FlowJo software
version 6.3.2 (Tree Star Inc., Ashland, OR). Mouse lung
tissue was ﬁnely minced and digested with 0.1 collagenase A
(Roche Diagnostics), 2.4 units/mL dispase (Roche Diag-
nostics), and 6 units/mLDNase I (Qiagen) at 37C for 1 hour.
Debris was removed by sequential ﬁltration through 70 and
40 mm ﬁlters (BD Bio-sciences). Cells were stained with
ﬂuorochrome-conjugated mouse-speciﬁc antibodies (T cells
CD3-PE/CD45-APC, B cells B220-PE/CD45-APC, macro-
phages CD11b-FITC/F4/80-PE, granulocytes Ly6G-FITC/
CD45-APC, and dendritic cells CD11b-FITC/CD11c-PerCP)
from BD Biosciences.
Statistical Analysis
All data were analyzed by Student’s paired t-test. Mouse
data were also subjected to one-way analysis of variance
with Bonferroni post hoc). The level for statistical signiﬁ-
cance was set at P < 0.05.
Results
GATA-6 Levels are Markedly Decreased in the
Pulmonary Vasculature of SSc-PAH and IPAH Patients
We ﬁrst examined expression of GATA-6 protein in lung
specimens from nine patients with SSc-PAH, ﬁve patients
with IPAH, and four healthy controls.Representative stainingsFigure 1 GATA-6 levels are decreased in the pulmonary vasculature of SSc-PA
healthy controls, ﬁve IPAH, and nine SSc-PAH patients were analyzed for GATA-6
positively or negatively stained ECs in occluded and nonoccluded arterioles (A), and
Percentage of positively stained ECs in both occluded and nonoccluded arterioles and
lung tissues] were plotted on a scatter plot. *P< 0.01. In situ hybridization of paraf
analyze GATA-6 mRNA levels Arrows point to GATA-6 positive or negative ECs in the
panel). Original magniﬁcation, 400. Scale bars: 50 mm (AeC).
2396are shown in Figure 1, A and B. In healthy controls, GATA-6
protein was detected in the nuclei of alveolar type II cells,
VSMCs, and ECs; however, peripheral, slight, or no nuclear
staining could be detected in ECs of SSc-PAH tissue and slight
or no nuclear staining for GATA-6 could be seen in ECs of
IPAH tissue. GATA-6 positive EC nuclei were counted in
arterioles and venules for each lung specimen (Figure 1, A and
B, respectively). The analysis revealed a signiﬁcant reduction
of GATA-6 in both vessel types, including occluded and
nonoccluded, in both SSc-PAH and IPAH patients. Reduced
expression of GATA-6 was also observed in the capillaries of
PAH patients. In addition, GATA-6 protein levels were dras-
tically decreased in VSMCs, but there were no apparent
changes in the expression of GATA-6 in alveolar type II cells.
To further analyze if GATA-6 is decreased at themRNA level,
we performed in situ hybridization studies (Figure 1C). The
results demonstrated that GATA-6 is abundantly expressed in
ECs lining arterioles and venules in normal controls, but is
strikingly decreased in ECs lining both vessel types in IPAH
patients. These observations suggest that GATA-6 deﬁciency
may contribute to vessel remodeling during PAH.GATA-6 Regulates Expression of Genes Involved in
Vascular Remodeling
In an effort to begin to understand how loss of GATA-6 in
ECs may contribute to vascular remodeling, we sought to
identify genes regulated by GATA-6. To this end, we used
a commercially available EC PCR array (SABiosciences,
Valencia, CA) and performed the analyses in HPAECs afterH and IPAH patients. A and B: Parafﬁn-embedded tissue sections from four
using the standard avidin-biotin-peroxidase methodology. Arrows indicate
venules (B) of healthy individuals, IPAH patients, and SSc-PAH patients. C:
venules [in normal (bullets), IPAH (open diamonds) and SSC-PAH (triangles)
ﬁn-embedded tissue from healthy individuals and IPAH patients were used to
indicated vessels of healthy controls (top panel) or IPAH patients (bottom
ajp.amjpathol.org - The American Journal of Pathology
GATA-6 Regulates Vessel Remodelingsuppression of GATA-6 with siRNA oligos. This screen
identiﬁed genes involved in vessel tone and permissibility
(eNOS, ACE, EDNRA, ET-1), EC activation (CX3CL1, PAI-
1, RhoB, 5-lipoxygenease-activating protein [FLAP]), matrix
remodeling (MMP1, MMP10), and EC injury (PLA2G4C )
(for complete list of genes, see Table 4). mRNA levels of
putative target genes were examined by RT-qPCR. As shown
in Figure 2A, levels of mRNA for PLA2G4C, FLAP, RhoB,
MMP1, MMP10, PAI-1, CX3CL1, ACE, EDNRA, and ET-1
were elevated, whereas levels of eNOS were decreased
after suppression of GATA-6. Western blot analysis and
ELISA also conﬁrmed differential expression of eNOS,
MMP-1, MMP-10, PAI-1, RhoB, and CX3CL1 at the
protein level (Figure 2, B and C, respectively). These data
strongly suggest that GATA-6 may play a role in PAH by
regulating genes that promote vascular remodeling and
dysfunction. To further investigate if GATA-6 is a direct
transcriptional regulator of these genes, we performed
chromatin immunoprecipitation analysis. Putative GATA
sites were identiﬁed using Tfsitescan. As shown in
Figure 2D and Table 5, GATA-6 occupied one or more sites
on the promoters of FLAP, RhoB, MMP10, MMP1, PAI-1,
CX3CL1, eNOS, EDNRA, and ET-1, indicating that
GATA-6 is a direct regulator of these genes. We were not
able to detect GATA-6 binding on the PLA2G4C promoter.
Finally, as an additional negative control, we were not able
to immunoprecipitate the promoter of VE-Cadherin, a gene
that is not regulated by GATA-6 according to our micro-
array data.
GATA-6 Down-Regulation is an Early Event in the
Chronic Hypoxia Mouse Model and the MCT Rat Model
of PAH
Because endothelial GATA-6 deﬁciency affected expres-
sion of genes previously implicated in the development of
PAH, we next determined the levels of expression of
GATA-6 in two rodent models of PAH, the chronic
hypoxia mouse model, and the MCT rat model. A signif-
icant decrease of Gata-6 expression was already noticeable
at 3 days after hypoxia and expression decreased further
at 7 and 21 days (Figure 3A). Several of the GATA-6
target genes, including Pla2G4C, RhoB, EDNRA, and
Pai-1 were increased, whereas, surprisingly, Cx3cl1 grad-
ually decreased starting at day 3 (Figure 3B). Furthermore,
hypoxia inducible factor (Hif) subunits Hif1a, Hif1b, and
Hif2a showed the most pronounced upregulation at day 3
(Figure 3B) with signiﬁcantly elevated levels continuing
for the duration of the experiment (up to 2 months)
(Supplemental Figure S1).
Next we investigated if Gata-6 expression is decreased after
MCT injury (Supplemental Figure S2, AeE). Gata-6 expres-
sion was signiﬁcantly decreased as early as 3 days and further
gradually decreased up to 20 days postinjection. Gata-6
protein levels are also decreased in the lung tissue of rats
challenged with MCT after 20 days. These ﬁndings indicateThe American Journal of Pathology - ajp.amjpathol.orgthat GATA-6 expression levels are down-regulated at both
early and late stages of disease in two animal models of PAH.
GATA-6 Deﬁciency Augments mRNA Expression of
Endothelial HIF2a and HIF1b
To study the involvement of altered Gata-6 expression in the
vasculature in vivo, we selectively reduced expression of the
Gata-6 gene in ECs by crossing an established, commercially
available mouse line harboring a conditional loss-of-function
allele of Gata-6 with mice expressing Cre recombinase under
the control of the endothelial-speciﬁc VE-Cadherin promoter
to generate Gata-6ﬂox/ﬂox/VEcadCreþ/ mice (Gata6-KO).
Sex-matched littermates lacking the Cre allele were used as
controls. Isolation of pulmonary ECs from Gata6-KO mice
and controls demonstrated that Gata-6 expression is reduced
by 65% (Figure 3C).
After exposure to chronic hypoxia down-regulation of
Gata-6 correlated with upregulation of Hif1a and Hifb and
Hif2a, we next assessed the contribution of endothelial Gata-6
to the upregulation of Hif subunits using Wt and Gata6-KO
mice. Pulmonary ECs (CD31þ/CD45) were sorted by FACS
at days 1, 3, 5, and 7, and were directly used for mRNA
analysis. In Wt mice, a gradual decrease of Gata-6 expression
starting at day 1 of hypoxia was observed, whereas a rapid
increase of Hif1a occurred at day1, then gradually returned to
control levels by day 7 (Figure 3D). A similar pattern of ex-
pression was also observed for Hif1b and Hif2a. These data
suggest that ECsmay contribute to the initial upregulation, but
not to the prolonged activation of Hif genes in response to
hypoxia. Interestingly, pulmonary ECs isolated from Gata6-
KO mice showed increased baseline expression of Hif1a
and Hif1b, as well as Hif2a. Similar to Wt mice, a further
transient increase of Hif gene expression was observed in
Gata6-KO ECs. The Gata-6 mRNA levels in Gata6-KO mice
were comparable to the levels in Wt mice. To determine
whether GATA-6 could directly contribute to the upregulation
of HIF genes, HIF1a, Hif1b, and HIF2a were analyzed in
HPAECs after suppression of GATA-6 with siRNA oligos.
As shown in Figure 3E, expression of HIF1b and HIF2a was
signiﬁcantly increased, whereas expression of HIF1a
remained unchanged after depletion of GATA-6. Together,
these data suggest that absence of endothelial GATA-6 may
exacerbate effects of hypoxia in pulmonary vasculature.
GATA-6 Deﬁciency Leads to Elevated Pulmonary
Arterial Pressure
At 12 weeks of age, mice were subjected to echocardio-
graphical imaging before and after exposure to chronic
hypoxia. Using pulsed-wave Doppler of PA ﬂow, PAT, and
ejection time were measured (Figure 4A). This noninvasive
assessment of PAH has been validated in mice as a sensitive
method to assess changes in RV systolic pressure.28 Gata6-
KO mice had signiﬁcantly lower PAT at baseline compared
to Wt, which lowered signiﬁcantly more after exposure to2397
Table 4 The Human Endothelial Cell Biology RT2 Proﬁler PCR Array Gene List
Description
Up-regulation and down-regulation
(compared to control group)
Symbol
Group 1
Fold regulation
Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 ACE 2.3457
ADAM metallopeptidase domain 17 ADAM17 1.2746
Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT 1.014
Angiotensin II receptor, type 1 AGTR1 1.014
Arachidonate 5-lipoxygenase ALOX5 1.954
Angiopoietin 1 ANGPT1 1.014
Annexin A5 ANXA5 1.0425
BCL2-associated X protein BAX 1.1647
B-cell CLL/lymphoma 2 BCL2 1.3566
BCL2-related protein A1 BCL2A1 1.454
BCL2-like 1 BCL2L1 1.5801
Chemokine (C-X-C motif) receptor 5 CXCR5 1.014
Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) CASP1 1.0281
Caspase 3, apoptosis-related cysteine peptidase CASP3 1.007
Caspase 6, apoptosis-related cysteine peptidase CASP6 1.1728
Chemokine (C-C motif) ligand 2 CCL2 1.3379
Chemokine (C-C motif) ligand 5 CCL5 1.0644
Cadherin 5, type 2 (vascular endothelium) CDH5 1.1173
CASP8 and FADD-like apoptosis regulator CFLAR 1.3104
Collagen, type XVIII, alpha 1 COL18A1 1.2834
Carboxypeptidase B2 (plasma) CPB2 2.941
CASP2 and RIPK1 domain containing adaptor with death domain CRADD 2.0705
Colony stimulating factor 2 (granulocyte-macrophage) CSF2 1.014
Chemokine (C-X3-C motif) ligand 1 CX3CL1 2.7895
Thymidine phosphorylase TYMP 1.3472
Endothelin 1 EDN1 1.4044
Endothelin 2 EDN2 1.014
Endothelin receptor type A EDNRA 2.395
Fas (TNF receptor superfamily, member 6) FAS 1.1019
Fas ligand (TNF superfamily, member 6) FASLG 1.014
Fibroblast growth factor 1 (acidic) FGF1 1.014
Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular
permeability factor receptor)
FLT1 1.1408
Fibronectin 1 FN1 1.5263
Intercellular adhesion molecule 1 ICAM1 1.434
Interferon, beta 1, ﬁbroblast IFNB1 1.7654
Interleukin 11 IL11 1.7901
Interleukin 1, beta IL1B 1.5134
Interleukin 3 (colony-stimulating factor, multiple) IL3 1.014
Interleukin 6 (interferon, beta 2) IL6 1.1408
Interleukin 7 IL7 1.1567
Integrin, alpha 5 (ﬁbronectin receptor, alpha polypeptide) ITGA5 1.2834
Integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) ITGAV 1.0425
Integrin, beta 1 (ﬁbronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) ITGB1 1
Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 1.2924
Kinase insert domain receptor (a type III receptor tyrosine kinase) KDR 1.2658
V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog KIT 1.0867
Kallikrein-related peptidase 3 KLK3 1.014
Matrix metallopeptidase 1 (interstitial collagenase) MMP1 2.0705
Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) MMP2 1.2658
Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) MMP9 3.7412
Nitric oxide synthase 2, inducible NOS2 1.2658
Nitric oxide synthase 3 (endothelial cell) NOS3 2.3134
(table continues)
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Table 4 (continued )
Description
Up-regulation and down-regulation
(compared to control group)
Symbol
Group 1
Fold regulation
Natriuretic peptide B NPPB 1.014
Natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A) NPR1 1.1329
Occludin OCLN 1.014
Platelet-derived growth factor receptor, alpha polypeptide PDGFRA 1.9211
Platelet/endothelial cell adhesion molecule PECAM1 1.1567
Platelet factor 4 PF4 1.0425
Placental growth factor PGF 1.0867
Phospholipase A2, group IVC (cytosolic, calcium-independent) PLA2G4C 1.8703
Plasminogen activator, tissue PLAT 1.4845
Plasminogen activator, urokinase PLAU 1.5476
Plasminogen PLG 1.014
Prostaglandin I2 (prostacyclin) synthase PTGIS 1.5443
Ras homolog gene family, member B RHOB 1.7443
Receptor (TNFRSF)-interacting serine-threonine kinase 1 RIPK1 1.0497
Selectin E SELE 1.1251
Selectin L SELL 1.9754
Selectin P ligand SELPLG 1.014
Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 SERPINE1 2.2658
Superoxide dismutase 1, soluble SOD1 1.0353
Sphingosine kinase 1 SPHK1 1.2483
TEK tyrosine kinase, endothelial TEK 1.1567
Tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) TFPI 1.0943
Thrombomodulin THBD 1.1251
Thrombospondin 1 THBS1 1.3013
TIMP metallopeptidase inhibitor 1 TIMP1 1.1096
Tumor necrosis factor TNF 1.014
Tumor necrosis factor, a-induced protein 3 TNFAIP3 1.4044
Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain TNFRSF10C 1.0792
Tumor necrosis factor (ligand) superfamily, member 10 TNFSF1 1.2397
Vascular cell adhesion molecule 1 VCAM1 1.2397
Vascular endothelial growth factor A VEGFA 1.7171
Von Willebrand factor VWF 1.1567
Beta-2-microglobulin B2 mol/L 1.2142
Hypoxanthine phosphoribosyltransferase 1 HPRT1 1.1173
Ribosomal protein L13a RPL13A 1.0281
Glyceraldehyde-3-phosphate dehydrogenase GAPDH 1.1173
Actin, beta ACTB 1.5052
Human genomic DNA contamination HGDC 1.014
Reverse transcription control RTC 1.2658
Reverse transcription control RTC 1.257
Reverse transcription control RTC 1.3379
Positive PCR control PPC 1.0497
Positive PCR control PPC 1.4743
Positive PCR control PPC 1.2658
ADAM, A-disintegrin and metalloproteinase; BCL2, B cell lymphoma 2; CASP8, cysteine-aspartic protease 8; CLL, chronic lymphoid leukemia; FADD,
fas-associated protein with death domain; TEK, tyrosine kinase endothelial; TIMP, tissue inhibitor of metalloproteinases; TNF, tumor necrosis factor.
GATA-6 Regulates Vessel Remodelinghypoxia for 2 months (Supplemental Figure S3). PAT was
decreased in Wt after exposure to chronic hypoxia, indic-
ative of PAH. PAT/ejection time was also lower in
Gata6-KO than Wt under normoxic conditions and sig-
niﬁcantly lower in both Wt and Gata6-KO mice after
hypoxic insult for 1 and 2 months. To conﬁrm the presenceThe American Journal of Pathology - ajp.amjpathol.orgof increased PA pressure among Gata6-KO mice, we also
performed right heart catheterization (Figure 4B). RV
systolic pressure was signiﬁcantly elevated in Gata6-KO
mice compared to Wt mice at baseline, and signiﬁcantly
increased in both Wt and Gata6-KO mice after exposure to
hypoxia for 1 month.2399
Figure 2 GATA-6 regulates genes involved in vascular remodeling. HPAECs were transfected with control or small interfering RNA against GATA-6 oligos for
72 hours. Samples were assayed by RT-qPCR to determine mRNA levels (A) or by Western blot analysis (B) and ELISA (C) to determine protein levels for the genes
indicated. The experiments were performed at least three times and representative blots are shown. Band intensities were quantiﬁed by densitometric analysis.
Black bars, control siRNA; grey bars, Gata6 siRNA treated cells. *P< 0.05, **P< 0.01. D: Chromatin immunoprecipitation assays were performed in HPAECs using
rabbit antieGATA-6 polyclonal antibody or rabbit IgG. The experiments were performed at least three times and representative gels are shown.
Ghatnekar et alSystolic blood pressure, diastolic blood pressure, mean
pressure, heart pulse rate, and blood volume appeared to be no
different in the Gata6-KO mice (Table 6). Heart morphology
was investigated by serially sectioning hearts frombothWt and
Gata6-KO mice housed in both hypoxic and normoxic condi-
tions. There were no observed defects in valve morphology in
Gata6-KO mice in comparison to Wt controls. Furthermore,
there was no evidence of intramyocardial shunting of blood, as
there were no detectable septal defects in Gata6-KO mice in
either hypoxic or normoxic conditions. Myocardial histology
also appeared normal (Supplemental Figure S4).Table 5 Summary of Results for ChIP Analysis
Gene Predicted putative GATA binding site
PLA2G4C 982 to 977, 962 to 957
FLAP 1101 to 1096
RhoB 1877 to 1872, 1731 to 1726,
862 to 857
MMP-10 1831 to 1826, 1798 to 1793
1573 to 1568
994 to 989
226 to 221
MMP-1 1356 to 1351, 1323 to 1318
1112 to 1107, 982 to 977, 955 to 950
PAI-1 1691 to 1686
572 to 567
431 to 426
CX3CL1 881 to 876, 801 to 796
eNOS 1114 to 1109
203 to 198
EDNRA 767 to 762
495 to 490
328 to 323
ET-1 1207 to 1202, 1154 to 1149
745 to 740, 701 to 696, 681 to 676
136 to 131
ChIP, chromatin immunoprecipitation.
2400We concluded from these experiments that a reduction of
Gata-6 alone is enough to alter the PA pressure in mice and
that loss of Gata-6 leads to more severe changes in hemo-
dynamics under hypoxia.
GATA-6 Deﬁciency Leads to Worsened Vascular
Remodeling and RV Hypertrophy in Hypoxic Mice
To investigate the effect of decreased Gata-6 levels on
pulmonary vascular remodeling, the degree of musculari-
zation and the medial wall thickness of intra-acinar PAs (20Ampliﬁed regions of
target gene promoter
In vivo binding
of GATA-6
1081 to 878 þ
1134 to 966 þ
1908 to 1689 þ
1034 to 801 
1922 to 1721 þ
1650 to 1428 
1112 to 885 
270 to 114 þ
1435 to 1200 þ
1137 to 907 
1739 to 1556 þ
677 to 490 þ
510 to 305 þ
958 to 755 þ
1220 to 1000 
300 to 119 þ
846 to 650 
568 to 421 
420 to 261 þ
1298 to 1107 
849 to 652 
254 to 68 þ
ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Gata-6 expression and target genes are altered in the lungs of
hypoxic mice. Lung samples from control mice housed under normoxic
conditions (baseline) and mice exposed to hypoxic conditions for 3, 7, and
21 days were assayed by RT-qPCR to determine mRNA levels of Gata-6 (A)
and putative target genes (B). Levels are relative to baseline (normoxic)
animals. *P < 0.05, **P < 0.01 (n Z 3 to 5 per group). C: A mouse line,
which contains LoxP elements in introns ﬂanking exon 2 of the Gata-6 gene
(Jackson Laboratory), were bred with mice expressing Cre recombinase
under the control of the endothelial-speciﬁc VE-cadherin promoter. The
mRNA levels of GATA-6 were determined in pulmonary ECs isolated from Wt
and Gata6-KO (KO) neonate mice by RT-qPCR. *P < 0.01. D: Pulmonary ECs
isolated from both Wt and KO mice exposed to either normoxia or hypoxia
for 1, 3, 5, or 7 days. In each group, cells were pulled together from three
animals and assayed by RT-qPCR to determine mRNA levels of the genes
indicated. E: HPAECs were transfected with control or siGATA-6 oligos for 72
hours. Samples were assayed by RT-qPCR to determine mRNA levels for the
genes indicated. *P < 0.05, **P < 0.01.
GATA-6 Regulates Vessel Remodelingto 70mm in diameter) were analyzed in normoxic and hypoxic
conditions. Morphometric analysis revealed a signiﬁcant
difference between Gata6-KO mice and control animals
under both conditions. Furthermore, severe enhanced PA
muscularization seen by enhanced immunoreactivity for
a-SMA actin was observed in Gata6-KO mice subjected to
hypoxia for 1 month (Figure 5A). The analysis revealed
signiﬁcantly more fully and partially muscularized vessels in
the Gata6-KO mice and less nonmuscularized vessels
(Figure 5B). Under hypoxia,Gata6-KOmice had an evenmore
dramatic increase in fully muscularized vessels, as well as
a marked decrease in nonmuscularized vessels. In addition, the
medial wall thickness was signiﬁcantly increased in Gata6-KO
mice under hypoxic conditions (Figure 5C). Finally, we
observed that Gata-6-KO hypoxic mice also had signiﬁcantly
larger right ventricles as evidenced by an increase in the ratio of
RV to left ventricular (LV) plus septum weight (RV/[LVþS])
as compared to control littermates (Figure 5D).The American Journal of Pathology - ajp.amjpathol.orgGATA-6 Deﬁciency Induces Pathological Changes in
Pulmonary Gene Expression in Vivo
Next we analyzed the levels of GATA-6 target genes found
earlier in HPAECs (Figure 2) in the lungs of Gata6-KO and
control animals under both normoxic and hypoxic condi-
tions. Under normoxia, the pattern of gene expression in the
Gata-6 KO mice largely reproduced that of GATA-6-
deﬁcient HPAECs (Figure 6A). In particular, expression
of CX3CL1 and EDNRA was signiﬁcantly increased.
Changes in expression of other genes did not reach statis-
tical signiﬁcance, likely due to variability between the mice
and a small number of mice in each group (n Z 3 to 4);
however, they showed the same trends as HPAECs, with the
exception of matrix metalloproteinase 10 and 5-lipoxygenase
activating protein, which did not change in the Gata6-KO
mice. Several of the GATA-6 target genes, including
Pla2G4C, RhoB, EDNRA, and ET-1 were also upregulated in2401
Figure 4 GATA-6 deﬁciency induces hemodynamic changes in mice.
Pulmonary acceleration time (PAT) and PAT as a fraction of ejection time
(PAT/ET) (A) and RV systolic pressure (RVSP) (B) were measured in Wt and
Gata6-KO (KO) mice during normoxia (baseline) and after 1 month of
chronic hypoxia (see Materials and Methods). *P < 0.05 versus baseline;
yP < 0.05 versus Wt. n Z 3 to 4 per group.
Ghatnekar et alWt mice exposed to 1 month of hypoxia and were further
increased in hypoxic Gata6-KO mice (Figure 6B). A signiﬁ-
cant increase of RhoB and PAI-1 was observed after 2 months
of hypoxia inWtmice, and an evenmore pronounced increase
of those genes was observed in Gata-6-KO mice
(Supplemental Figure S1). Hif1a and Hif1b were modestly
elevated in normoxic Gata-6-KOmice, whereas expression of
all three factors was signiﬁcantly increased in Wt and Gata-6-
KO mice after 1 and 2 months of hypoxia (Figure 6B and
Supplemental Figure S1). Notably, expression of Cx3cl1 gene
was signiﬁcantly reduced in hypoxic Wt mice in comparison
to Wt mice from normoxic conditions and was also less
prominently increased in Gata6-KO mice from the hypoxicTable 6 Occlusion Tail-Cuff Measurements
Animal SBP DBP Mean BP HR Volume
Wt 1 92 67 74 628 27
Wt 2 107 79 88 674 39
Wt 3 108 79 89 454 32
Wt 4 82 59 66 606 30
KO 1 76 50 59 488 27
KO 2 92 69 76 666 34
KO 3 80 49 59 519 29
KO 4 130 111 117 702 33
BP, blood pressure; DBP, diastolic blood pressure; HR, heart rate;
KO, Gata6-KO; SBP, systolic blood pressure; Wt, wild-type.
2402conditions as compared to normoxia. Although, only a limited
number of genes have been analyzed, these data suggest that
the mechanisms of the vascular injury induced by hypoxia
share both common anddistinct pathwayswith those regulated
by GATA-6.Figure 5 Loss of GATA-6 leads to worsened vessel muscularization and
RV hypertrophy in mice exposed to hypoxia. A: Lungs and hearts from 12- to
16-week-old male Wt and Gata6-KO (KO) mice exposed to either normoxic or
hypoxic conditions for 1 month were subjected to morphometric analysis of
pulmonary vessels and RV hypertrophy measurements. Lung sections were
stained for von Willebrand factor (brown) and a-SMA (purple). Represen-
tative microphotographs are shown. Original magniﬁcation, 400. Scale
bars: 20 mm. B: Morphometry was performed on the double immunostained
lung sections. A total of 60 to 80 intra-acinar vessels ranging in 20 to 70 mm
in size were counted and categorized into nonmuscularized (N), partially (P)
muscularized, or fully (F) muscularized (see Materials and Methods). *P <
0.01. C: Percent wall thickness was measured in round fully muscularized PAs
(see Materials and Methods). D: The weight ratios of the right ventricle to the
left ventricle plus septum [RV/(LV þ Septum)] were calculated as indices of
RV hypertrophy. *P < 0.05.
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Figure 6 A: Gata-6 regulates genes involved in
vessel remodeling in vivo. Lung samples from
Gata6-KO (KO) mice and controls were assayed by
RT-qPCR to determine mRNA levels of putative
target genes. B: Lung samples from KO and control
Wt mice subjected to hypoxic conditions for
1 month were assayed by RT-qPCR to determine
mRNA levels of Gata-6 target genes relative to
control Wt mice housed in normoxic conditions.
*P < 0.05, **P < 0.01. n Z 3 to 5 per group.
GATA-6 Regulates Vessel RemodelingGATA-6 Deﬁcient Mice Show Persistent Inﬂammation
in Vivo
Given the persistently elevated expression of Cx3cl1 in
Gata6-KOmice, we sought to determine whether recruitment
of inﬂammatory cells to pulmonary vasculature is affected in
these mice. FACS analysis was performed on lung tissues
from Wt and Gata-6-KO mice in normoxic conditions and
after 1 month of hypoxia challenge. The number of T cells
(CD3þ/CD45þ) and B cells (B220þ/CD45þ) was similar in
Wt and Gata-6-KO mice under normoxia and was similarly
increased in both strains under hypoxia (Figure 7A). In
contrast, macrophages (CD11bþ/F4/80þ), granulocytes
(Ly6Gþ/CD45þ), and dendritic cells (CD11bþ/CD11cþ)
were signiﬁcantly increased in Gata-6-KO mice under nor-
moxic conditions, but did not differ signiﬁcantly in hypoxic
mice (Figure 7A). An increased presence of monocytes/
macrophages in Gata6-KO mice was further conﬁrmed in
lung tissue sections fromWt andGata6-KOmice (Figure 7B).Figure 7 Gata-6 (KO) deﬁciency leads to increased perivascular
inﬂammation. A: Single cell suspensions isolated from Wt and KO mice
exposed to both normoxia and hypoxia for 1 month were stained with
ﬂuorochrome-conjugated antibodies for the indicated cell surface proteins
and subjected to ﬂow cytometry analysis. *P < 0.05, **P < 0.01. B: Lung
sections from Wt and KO mice exposed to normoxic or hypoxic conditions
for 2 months were subjected to immunostaining for Mac3 using the stan-
dard avidin-biotin-peroxidase methodology. Immunoreactivity was detec-
ted using 3, 30-diaminiobenzidine substrate kit. Hematoxylin was used as
a counterstain. Arrows indicate positively stained macrophages. Original
magniﬁcation, 200. Scale bars: 10 mm.Discussion
All forms of PAH are characterized by severe pulmonary
vascular remodeling that leads to increased vascular resis-
tance and ultimately right heart failure. The molecular
mechanisms underlying the remodeling process and espe-
cially early pathogenic changes in the EC compartment
remain elusive. Herein, we show that down-regulation of
GATA-6 in ECs represents a key pathological event during
development of PAH. GATA-6 is reduced in ECs, as well as
smooth muscle cells of both occluded and nonoccluded
pulmonary vessels of both IPAH and SSc-PAH in vivo,
suggesting that reduction of GATA-6 is not a consequence of
late stage vessel remodeling, but occurs before vessel
occlusion and may reﬂect an early phase of EC activation
and/or dysfunction during PAH. This notion is supported byThe American Journal of Pathology - ajp.amjpathol.orgobservations from the two animal models of PAH, the MCT
rat model and the chronic hypoxia mouse model, that
show rapid reduction of the GATA-6 mRNA levels in the
lungs after injury (at 3 days). Regulatory pathways that
are involved in GATA-6 down-regulation remain to be
elucidated.2403
Ghatnekar et alCharacterization of Gata6-KO mice revealed that GATA-
6 is particularly important for pulmonary hemodynamics
because a loss of GATA-6 alone was sufﬁcient to raise PA
pressure, but not systemic blood pressure. This may be due,
in part, to enhanced vasoconstriction caused by changes in
the levels of regulators of vascular tone (eNOS and ET-1).
The eNOS null mice develop mild PAH under normoxic
conditions and severe PAH under slightly hypoxic condi-
tions.29 Impaired bioavailability of active nitric oxide is
a major underlying feature of most clinical and experimental
forms of PAH.30 Furthermore, ET-1, as well as endothelin-1
receptor type A, was signiﬁcantly increased after down-
regulation of GATA-6 by siRNA in cultured HPAECs and
in Gata6-KO mice. ET-1 is a potent vasoconstrictor, a mitogen
for pulmonary VSMCs, and a ﬁbrogenic mediator.31 Plasma
levels of ET-1 are elevated in PAH and are inversely propor-
tional to the levels of pulmonary blood ﬂow and cardiac
output.32,33 Moreover, a recent study has linked EDNRA
polymorphism to an increased susceptibility to PAH.34
Evidence suggests that inﬂammatory events may contribute
to the pathogenesis of various forms of PAH, including IPAH
and SSc-PAH.35,36 It has also been suggested that inﬂamma-
tory pathways and autoimmunity play amore prominent role in
SSc-PAH versus IPAH and may contribute to the differential
response to therapy between the two syndromes.37 This study
identiﬁed CX3CL1 (fractalkine) as one of the GATA-6 direct
target genes. To our knowledge, this is the ﬁrst demonstration
that GATA-6 functions as a transcriptional repressor of the
CX3CL1 gene. Elevated levels of fractalkine have been
observed in inﬂammatory lung diseases including chronic
obstructive pulmonary disease and PAH.38 Fractalkine was
also found in the top 20most upregulated genes inSSc-PAHby
a recentmicroarray analysis.10 In humanPAH,ECswere found
to be the main source of CX3CL1 in the PA.39 In addition to
recruiting inﬂammatory cells, CX3CL1 has been shown to act
as a mitogenic agent on VSMCs in atherosclerosis40 and as an
inducer of angiogenesis via stimulation of HIF-1a/vascular
endothelial growth factor-A axis,41 suggesting that fractalkine
may regulate various pathological aspects of PAH. Interest-
ingly, although Gata-6 expression was reduced in hypoxia in
Wt mice, we also observed concomitant reduction of Cx3cl1,
suggesting that hypoxia-driven pathways supersede the effect
of Gata-6 down-regulation. These ﬁndings corroborate an
earlier in vitro study that demonstrated hypoxia-mediated
inhibition of interferon-g-induced Cx3cl1 in ECs.42
In addition to its effect on fractalkine expression, GATA-6
may regulate cytokine release by directly controlling ex-
pression of FLAP, which activates 5-lipooxygenase. It is
possible that 5-lipooxygenase plays an early role in triggering
a pro-inﬂammatory environment because its activation and
translocation to the nuclear membrane are required for the
production of leukotrienes, which are known to induce
cytokine release.43 Both 5-lipooxygenase and FLAP have
been shown to be upregulated in PAs of IPAH patients, and
inhibition of FLAP in hypoxic rats ameliorates pulmonary
hypertension and vascular reactivity.44,452404A reduction of Gata-6 alone signiﬁcantly altered the PA
pressure in mice, and increased vascular remodeling and
inﬁltration of inﬂammatory cells under basal conditions. Per-
ivascular inﬂammation is present in other animal models of
PAH and in human PAH, however, the role of inﬂammatory
cells in the disease process is not yet clear.46 It is important to
note that in our model, Gata-6 was deleted from ECs only,
whereas in patients with PAH, both endothelial and smooth
muscle cells were deﬁcient for GATA-6. Also, GATA-6 may
have a distinct role in endothelial and smoothmuscle cells, and
its absence in both cell types would likely result in a more
severe phenotype. As shown herein, Gata-6 expression in ECs
was gradually decreased after treatment of mice with chronic
hypoxia, suggesting that hypoxic conditions may be in part
responsible for the changes in Gata-6 levels in patients with
PAH. Further studies are needed to determine whether
GATA-6 is also regulated by hypoxia in smooth muscle cells.
In SSc, endothelial injury resulting in the structural changes
in the microvasculature and autoimmunity are the earliest
manifestations of the disease.47 Although PAH develops only
in a subset of patients, survival of SSc-PAH patients is very
poor as compared to IPAH.9 In addition to pulmonary vessels,
we have also observed decreased levels of GATA-6 in the
dermis of the majority of SSc patients (Ghatnekar and Troja-
nowska, unpublished data) supporting the notion that chronic
systemic changes in the vasculature occurring in various
organs may be the principal reason for the differences in
survival between these two diseases. In conclusion, we
describe a novelmodel of PAHcharacterized byEC injury and
persistent inﬂammation thatmay provide new insights into the
role of endothelial-immune axis during development of PAH.
We believe that this new model will be particularly informa-
tive in dissecting the mechanisms involved in SSc-PAH.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.02.039.
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